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ABSTRACT
Hemorrhagic cystitis (HC) is a well-documented adverse event experienced by patients undergoing hemato-
poietic stem cell transplantation. When severe, HC causes significant morbidity, leads to renal complications,
prolongs hospitalization, increases health-care costs, and occasionally contributes to death. We retrospectively
studied the medical records of 245 children undergoing an initial allogeneic bone marrow transplantation for
malignant disease at St. Jude Children’s Research Hospital between 1992 and 1999 to describe the clinical
course of HC in all patients and to identify the risk factors for HC in this cohort. Conditioning regimens
included cyclophosphamide, cytarabine, and total body irradiation. Grafts from unrelated or mismatched
related donors were depleted of T lymphocytes, whereas matched sibling grafts were unmanipulated. All
patients received cyclosporine as prophylaxis for graft-versus-host disease. Recipients of grafts from matched
siblings also received pentoxifylline or short-course methotrexate. Severe HC developed in 27 patients
(11.0%). The median duration of HC was 73 days (range, 5-619 days); 12 patients had ongoing HC at the time
of death. In univariate analyses, patients were at increased risk of severe HC if they were male (P  .021) or
had received T cell–depleted grafts (P .017), grafts from unrelated donors (P .021), a lower total nucleated
cell dose (P .032), or antithymocyte globulin (P .0446). Multiple regression analysis revealed male sex ( 
.97; P  .027) and unrelated donor graft recipients (  .83; P  .039) to be significant factors.
© 2003 American Society for Blood and Marrow Transplantation
KEY WORDS
Hemorrhagic cystitis ● Bone marrow transplantation ● Adenovirus ● Complications ●NTRODUCTION
Hemorrhagic cystitis (HC) is a signiﬁcant cause of
orbidity and, occasionally, mortality in patients un-
ergoing hematopoietic stem cell transplantation
HSCT) [1-3]. As many as 25% of patients experience
his complication after allogeneic HSCT; lower rates
re reported in autograft recipients. The severity of
C can range from mild hematuria to life-threatening p
98leeding with urinary tract obstruction or renal insuf-
ciency [4,5]. HC is thought to be caused by bacterial
r viral urinary tract infections or by certain condi-
ioning regimens [1,2,6]. To our knowledge, this is the
argest published report to describe the clinical course
f HC and the risk factors for its development in
hildren undergoing allogeneic bone marrow trans-Pediatrics
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PATIENTS AND METHODS
Patients
We reviewed the records of 245 consecutive chil-
dren who underwent allogeneic BMT for malignant
disease after a myeloablative preparative regimen be-
tween 1992 and 1999 at our institution. Patients were
treated on institutional protocols approved by the in-
stitutional review board. The characteristics of these
patients are shown in Tables 1 and 2. Class I HLA
antigens were typed serologically, and class II antigens
were typed by high-resolution DNA typing.
Conditioning Regimen
Patients received cytarabine (3 g/m2 per dose; 6
doses) and cyclophosphamide (45 mg/kg per dose; 2
doses) with mesna uroprotection [7]. They also re-
Table 1. Patient Characteristics
Feature Category HC (n  27) Control (n  218) Total (n  245)
Diagnosis ALL/NHL 8 (29.6%) 59 (27.1%) 67 (27.4%)
AML/MDS 14 (51.9%) 125 (57.3%) 139 (56.7%)
CML 5 (18.5%) 34 (15.6%) 39 (15.9%)
Outcome Dead 17 (63.0%) 122 (56.0%) 139 (56.7%)
Alive 10 (37.0%) 96 (44.0%) 106 (43.3%)
T-Cell depleted Yes 23 (85.2%) 135 (61.9%) 158 (64.5%)
No 4 (14.8%) 83 (38.1%) 87 (35.5%)
TBI Yes 27 (100%) 217 (99.5%) 244 (99.6%)
No 0 1 (0.5%) 1 (0.4%)
ATG Yes 18 (66.7%) 100 (45.9%) 118 (48.2%)
No 9 (33.3%) 118 (54.1%) 127 (51.8%)
Busulfan Yes 0 1 (0.5%) 1 (0.4%)
No 27 (100%) 217 (99.5%) 244 (99.6%)
Donor CMV Negative 15 (55.6%) 123 (56.4%) 138 (56.3%)
Positive 12 (44.4%) 95 (43.6%) 107 (43.7%)
Recipient CMV Negative 14 (51.9%) 115 (52.8%) 129 (52.7%)
Positive 13 (48.2%) 103 (47.3%) 116 (47.4%)
Prior autologous transplantation Yes 4 (14.8%) 18 (8.3%) 22 (9.0%)
No 23 (85.2%) 200 (91.7%) 223 (91.0%)
Donor MMFM 2 (7.4%) 31 (14.2%) 33 (13.5%)
Matched sibling 4 (14.8%) 79 (36.2%) 83 (33.9%)
Unrelated 21 (77.8%) 108 (49.5%) 129 (52.7%)
Donor-recipient sex match Male-male 12 (44.4%) 53 (24.3%) 65 (26.5%)
Female-female 5 (18.5%) 68 (31.2%) 73 (29.8%)
Male-female 2 (7.4%) 40 (18.4%) 42 (17.1%)
Female-male 8 (29.6%) 57 (26.2%) 65 (26.5%)
Acute GVHD Grade (II, III, IV) 5 (18.5%) 53 (24.3%) 58 (23.7%)
Grade (0,1) 22 (81.5%) 165 (75.7%) 187 (76.3%)
Chronic GVHD Yes 6 (22.2%) 37 (17.0%) 43 (17.6%)
No 21 (77.8%) 181 (83.0%) 202 (82.5%)
ALL indicates acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; AML, acute myelogenous leukemia; MDS, myelodysplastic
syndrome; CML, chronic myelogenous leukemia; MMFM, mismatched family member.
Table 2. Descriptive Statistics Analysis Results
Variable HC* Control* P Value
Median age at BMT (y) 12.6 (3.50-21.9) 11.2 (0.08-24.1) .24
Median donor age (y) 30 (7.0-48) 26 (0.6-53) .19
Median T-cell dose (per kilogram) 8.89  105 (2.0  105-2.79  106) 1.0  106 (1.7  104-1.64  107) .11
Median total cell dose (per kilogram) 1.25  108 (1.9  107-4.37  108) 1.59  108 (1.96  107-4.69  109) .012
Median CD 34 cell dose (per kilogram) 2.3  106 (3.75  105-7.54  106) 2.26  106 (1.52  104-2.19  107) .43
Median cyclophosphamide dose (mg/kg) 89 (67-138) 89 (26-200) .47
Median follow-up (years after BMT) 0.73 (0.14-6.2) 0.98 (0.04-8.5)
Time to ANC > 500 (d) 20.5 (15-68) 19 (12-46) .35
Time to platelet > 20 (d) 33 (20-89) 33 (15-102) .26
Time to platelet > 50 (d) 37 (22-96) 33 (15-105) .23
Time to platelet > 100 (d) 43 (25-94) 38 (19-98) .17
ANC indicates absolute neutrophil count.
*Numbers in parentheses indicate range.
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ceived total body irradiation (TBI) in 8 fractions, for a
total of 12 Gy (matched sibling marrow recipients) or
14 Gy (unrelated or mismatched family member mar-
row recipients). One patient who could not receive
TBI was treated with busulfan (1 mg/kg per dose; 16
doses) and cyclophosphamide (50 mg/kg per dose; 4
doses) with mesna uroprotection. Antithymocyte
globulin (ATG) was administered as part of the pre-
transplantation conditioning regimen to 121 patients
who received marrow from unrelated or mismatched
family donors to enhance immunosuppression.
In all patients, cyclophosphamide was adminis-
tered as a 1-hour infusion. Hydration with intrave-
nous ﬂuids at 3 L/m2/d started at least 24 hours before
the initial cyclophosphamide dose and continued for
24 h after the conditioning regimen was complete.
Mesna (45 mg/kg divided into 5 doses) was adminis-
tered before and 3, 6, 9, and 12 hours after each dose
of cyclophosphamide [7].
Graft-versus-Host Disease Prophylaxis
Marrow from mismatched family members and
from unrelated donors was depleted of approximately
1.5 log T lymphocytes by use of monoclonal antibod-
ies to CD6 and CD8 plus rabbit complement [7]. Two
days before transplantation, all recipients began to
receive cyclosporine at dosages adjusted to yield
whole-blood concentrations of 200 to 350 ng/mL.
Patients given matched sibling marrow received addi-
tional graft-versus-host disease (GVHD) prophylaxis
with pentoxifylline or short-course methotrexate.
Toxicity
Acute and chronic GVHD were graded according
to standard criteria [8]. Patients with mild or moderate
GVHD (grade I or II) were treated with methylpred-
nisolone (1-2 mg/kg/d). If GVHD remained at grade
II for 7 days or progressed, the steroid dosage was
increased to 5 to 10 mg/kg/d or second-line therapy
with ATG or to the antibody ABX-CBL was initiated
[9]. Regimen-related toxicity was scored with the Na-
tional Cancer Institute common toxicity criteria. Se-
vere HC was deﬁned as National Cancer Institute
common toxicity criteria grade 2 to 4. Grade 2 HC
was deﬁned as gross hematuria without clots, treated
with hydration and diuresis. Persistent gross bleeding
or clots requiring transfusion or cauterization charac-
terized grade 3 HC. Patients with grade 4 HC had
resistant hematuria that required surgery. The worst
clinical presentation was deﬁned as the grade of HC.
The date of onset was the ﬁrst day of initial signs or
symptoms of HC. Early-onset HC was deﬁned as the
onset of HC signs or symptoms before posttransplan-
tation day 60; late-onset HC was deﬁned as the onset
of HC signs or symptoms after 60 days after trans-
plantation.
HC Screening and Management
HC screening and management was standardized
at our institution. Urinalysis was performed daily dur-
ing cyclophosphamide administration. Surveillance
urine cultures for bacteria and viruses were performed
on a weekly basis and when hematuria occurred. The
initial treatment for HC consisted of intravenous ﬂuid
hydration at 3 L/m2/d with diuretics. Platelet trans-
fusions were given to patients with thrombocytopenia.
Renal and bladder ultrasound was performed in pa-
tients with gross hematuria. When clinically indicated,
continuous bladder irrigation with saline or glycine
was performed and was titrated to keep a clear urine
outﬂow. For patients with persistent bleeding despite
these measures, cystoscopy was performed with clot
evacuation, with cauterization of bleeding sites if fo-
cal. If HC persisted, progressive instillation of alum,
silver nitrate, or formalin was performed. Three pa-
tients received systemic conjugate estrogens at the
discretion of the transplant physician.
Supportive Care
All patients with an absolute neutrophil count
1.0  109/L received trimethoprim/sulfamethox-
azole (co-trimoxazole 5 mg/kg/d divided into 2 doses)
3 times a week for Pneumocystis carinii pneumonia
prophylaxis. Patients who were seropositive for cyto-
megalovirus (CMV) or had a CMV-seropositive do-
nor received ganciclovir (5 mg/kg twice daily for 14
days) when the absolute neutrophil count exceeded
0.5  109/L for 2 consecutive days. A reduced dose (5
mg/kg/d for 5 days per week) was then given until day
120 after transplantation. Intravenous immunoglobu-
lin (500 mg/kg weekly) was given until day 120 and
was given monthly thereafter until 12 months after
transplantation. Patients had weekly viral culture and
shell vial assay performed on peripheral blood as sur-
veillance for CMV. Patients who received T cell–
depleted grafts were eligible to receive donor-derived
cytotoxic T cells speciﬁc for Epstein-Barr virus as
prophylaxis against Epstein-Barr virus lymphoprolif-
erative disease at approximately 60 days after trans-
plantation [10]. No prophylaxis for fungal infections
or veno-occlusive disease was routinely provided.
Statistical Methods
The Student t test was used to assess the difference
of distributions on the continuous variables between
the HC and control groups. The cumulative incidence
of HC was estimated by using the method of Prentice
et al. [11]. The effects of several categorical variables
were evaluated 1 at a time by using Gray’s method
[12]. However, for continuous variables and multiple
regression analyses, we used the proportional hazard
model for competing risk proposed by Fine and Gray
[13]. These variables included diagnosis, age at BMT,
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disease status at the time of BMT, donor type, TBI
conditioning regimen, ATG-containing conditioning
regimen, donor CMV serology, recipient CMV serol-
ogy, donor-recipient sex match, prior autologous
transplantation, cyclophosphamide dose, platelet en-
graftment, and the presence of acute or chronic
GVHD (Table 3). Univariate analysis was performed
ﬁrst to assess the effect of each factor. All factors
found to be signiﬁcant at the level of   .10 were
planned to be analyzed with a multiple regression
model. The length of time at risk for HC was com-
puted from the date of BMT to the date of the diag-
nosis of HC, the date of death, or the date of last
contact, whichever came ﬁrst. Death from any cause
was considered a competing event. The criterion for
signiﬁcance for all analyses was P  .05. All statistical
analyses used SAS release 8.1 (SAS Institute, Cary,
NC) and SPLUS 2000 (Mathsoft Inc, Seattle, WA).
RESULTS
Transplant Patient Characteristics
Two hundred forty-ﬁve patients with hematologic
malignancies underwent allogeneic BMT at our insti-
tution during the study period. The median age of
patients was 11.5 years (range, 0.08-24.1 years) at the
time of transplantation; 53% were male. Twenty-two
(9.0%) had received a prior autologous BMT. Dis-
eases for which BMT was performed included the
following: 67 patients (27%) had acute lymphoblastic
leukemia or non-Hodgkin lymphoma, 139 patients
(57%) had acute myelogenous leukemia or myelodys-
plastic syndrome, and 39 patients (16%) had chronic
myelogenous leukemia. Eighty-three (33.9%) patients
received grafts from HLA-matched sibling donors, 33
(13.5%) from mismatched family member donors, and
129 (52.7%) from unrelated donors. All patients re-
ceived cyclophosphamide, 1 (0.4%) patient received
busulfan, and 244 (99%) patients received TBI as part
of the conditioning regimen. Fifty-eight (23.7%) pa-
tients developed grade II to IV acute GVHD; 43
(17.6%) developed chronic GVHD.
HC Patient Characteristics
Severe HC developed in 27 patients, yielding a
cumulative incidence of 11%  2.0%. Of note, there
was no difference in time to neutrophil or platelet
engraftment between transplant recipients who did
and did not develop HC (Table 2). For HC patients,
the median age was 12.6 years (range, 3.5-21.9 years);
74% were male. The characteristics of patients who
did and did not experience HC are compared in Ta-
bles 1 and 2. HC began a median of 52 days (range,
10-347 days) after BMT, and 14 patients had early-
onset HC (Table 4). Patients with HC received a graft
with a lower total nucleated cell dose than the control
group (P  .012). Cultures of urine were positive for
adenovirus in 3 patients who had cystitis; CMV was
isolated from the urine of 1 patient who had HC, and
adenovirus was isolated from the throat of the same
patient. Adenovirus was identiﬁed in the stool of 1
patient, but this patient’s urine contained no patho-
Table 3. Univariate Analysis Results
Variable
2-y Cumulative
Incidence of HC
(%  SE) P Value
Patient sex
Male (n  130) 15.4  3.2 .021
Female (n  115) 6.1  2.2
Diagnosis
ALL/NHL (n  67) 11.9  4.0
AML/MDS (n  139) 10.1  2.6 .85
CML (n  39) 12.8  5.4
Donor
MMFM (n  33) 6.1  4.2
Matched sibling (n  83) 4.8  2.4 .021
Unrelated (n  129) 16.3  3.3
ATG
Yes (n  118) 15.2  3.3 .0446
No (n  127) 7.1  2.3
HUSTTP
Yes (n  28) 21.4  7.9 .062
No (n  217) 9.7  2.0
TCD
Yes (n  158) 14.6  2.8 .017
No (n  87) 4.6  2.3
Donor CMV
Positive (n  107) 11.2  3.1 .95
Negative (n  138) 10.9  2.7
Recipient CMV
Positive (n  116) 11.2  2.9 .90
Negative (n  129) 10.8  2.7
Donor recipient sex match
Male-male (n  65) 18.5  4.9
Female-female (n  73) 6.8  3.0 .082
Male-female (n  42) 4.8  3.3
Female-male (n  65) 12.3  4.1
Prior autologous transplantation
Yes (n  22) 18.2  8.5 .25
No (n  223) 10.3  2.0
Disease status at BMT
CP1/CR1 (n  89) 10.1  3.2
CP2/CR2 or more (n  51) 15.7  5.2 .50
Others (n  105) 9.5  2.9
Acute GVHD
Grade (0, I) (n  187) 11.8  2.4 .47
Grade (II, III, IV) (n  58) 8.6  3.7
Chronic GVHD
Yes (n  43) 13.9  5.3 .48
No (n  202) 10.4  2.1
Cell dose Continuous variable .032
Cyclophosphamide dose Continuous variable .38
ALL indicates acute lymphoblastic leukemia; NHL, non-Hodgkin
lymphoma; AML, acute myelogenous leukemia; MDS, myelo-
dysplastic syndrome; CML, chronic myelogenous leukemia;
MMFM, mismatched family member; HUSTTP, post-BMT
microangiopathy; CP, chronic phase; CR, continuous remission;
TCD, T-cell depleted.
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gens. Cystoscopy did not reveal any cytologic ﬁndings
suggestive of viral infection in any patient. Five
(18.5%) patients had grade II to IV acute GVHD, and
6 (22%) had chronic GVHD.
Clinical Course
Treatment interventions and outcomes are out-
lined in Table 4. All patients were treated with intra-
venous hydration and diuresis. Patients with throm-
bocytopenia were given platelet transfusions, and no
patient had evidence of immune-mediated platelet
consumption. These interventions alone led to reso-
lution of cystitis in 5 patients. Twenty-two (81%)
patients required continuous bladder irrigation (4 with
glycine), and 9 underwent cystoscopy with clot evac-
uation or cauterization of the sites of bleeding. Thir-
teen patients were treated with irrigation alone. Other
therapeutic interventions included instillation of silver
nitrate (n  4), alum (n  4), or formalin (n  7) or
administration of estrogens (n  3). Hydronephrosis
developed in 9 patients, of whom 3 patients required
ureteral stent placement and 2 required nephrostomy
tubes. Three patients required suprapubic catheters.
Two patients who received continuous bladder irriga-
Table 4. Clinical Course
Patient
No. Onset
Acute/
Chronic
GYHD CBI
Silver
Nitrate* Alum* Formalin* Estrogen
Renal
Failure Culture
HC
Duration
(d)
Resolution
of HC Outcome Comments
1 Late II/yes Yes 2 2 No No 176 No Died Fulguration,
suprapubic
catheter,
cystoscopy
2 Late I/no No No No 10 No Died
3 Late I/no Yes 1 1 2 Yes No 107 Yes Died
4 Late I/no Yes 2 No No 104 No Died Perforation
5 Late II/yes No No No 95 No Died
6 Late I/no Yes No No 117 No Died
7 Early I/no Yes 2 No No 144 No Died Ureteral
stents
8 Early I/no Yes No No 61 No Died Cystoscopy
9 Early 0/yes Yes 1 1 Yes No CMV urine,
adenovirus
throat
80 Yes Alive Cystoscopy
10 Early 0/no Yes No No 24 No Died
11 Late I/no No No No 48 No Died
12 Early 0/no No No No 12 Yes Alive
13 Early I/no Yes No No 20 Yes Alive
14 Early I/no Yes No No 69 Yes Alive
15 Early 0/no No No No 45 Yes Died
16 Late I/no Yes Yes No Adenovirus
urine
47 No Died
17 Early I/yes Yes 1 3 No Yes Adenovirus
urine
619 Yes Alive Ureteral
stents,
suprapubic
catheter,
perforation
18 Late 0/no Yes No No 146 Yes Alive Fulguration
19 Late I/no Yes No Yes 89 Yes Alive Nephrostomy,
suprapubic
catheter
20 Early I/yes Yes 1 No No Adenovirus
urine
73 Yes Alive Ureteral
stents,
cystoscopy
21 Late I/no Yes No No 8 Yes Died
22 Early II/yes Yes No No 129 Yes Died
23 Early 0/no Yes No No Adenovirus
stool
87 Yes Alive Cystoscopy
24 Late II/no Yes 2 No No 220 No Died Nephrostomy
25 Late 0/no Yes No No 5 Yes Died
26 Early I/no Yes 1 2 No Yes 66 Yes Alive Cystoscopy
27 Early II/no Yes No No 53 No Died
CBI indicates continuous bladder irrigation.
*Number of instillations.
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tion had perforated bladders, 1 of which was discov-
ered at autopsy. Renal failure occurred in 3 patients,
and 1 required hemodialysis. Urologists recom-
mended that 1 patient (patient 17) undergo cystec-
tomy; however, the family refused, and the patient
eventually recovered. No patient died as a direct result
of HC. Five of the patients who had resolution of HC
subsequently died of other causes not related to HC.
Twelve patients had ongoing HC at the time of death.
For these patients, HC lasted a median of 78 days
(range, 10-220 days). For survivors, the median dura-
tion of HC was 77 days (range, 12-619 days). For all
patients, the median duration of cystitis was 73 days
(range, 5-619 days). HC resolved in 15 patients, in-
cluding 2 of 3 patients treated with estrogens and 3 of
4 with documented viral infection.
Early-onset HC occurred in 14 patients (Table 4):
8 of these patients survived, and all had resolution of
HC. Of the 6 who died, only 2 had resolution of HC
before death. For patients with early-onset HC, causes
of death included infection (n  2), relapse (n  2),
respiratory failure (n  1), and multisystem organ
failure (n  1).
Late-onset HC occurred in 13 patients (Table 4);
only 2 of these patients survived. The survivors expe-
rienced resolution of cystitis, but only 3 of the 11
patients who died had resolution of HC before death.
For patients with late-onset HC, causes of death in-
cluded relapse (n  4), respiratory failure (n  3),
multisystem organ failure (n  1), adult respiratory
distress syndrome (n  2), and hepatic failure (n  1).
Risk Factor Analysis
The following factors were identiﬁed as being
associated with an increased risk of HC by univariate
analysis: (1) male gender (P  .021); (2) a graft with a
lower total nucleated cell dose (P  .032); (3) an
unrelated donor graft (P .021); (4) a T cell–depleted
graft (P .017); and (5) use of ATG (P .0446; Table
3). However, donor type, total cell dose, use of ATG,
and the use of T-cell depletion were statistically con-
founded with one another. For example, recipients of
unrelated and mismatched family member grafts re-
ceived T cell–depleted grafts and grafts with lower
nucleated cell doses than those who received matched
sibling grafts. In addition, ATG was not administered
to recipients of matched sibling grafts. Donor type
determined the use of ATG and whether a T cell–
depleted graft was used, and, thus, a lower cell dose
was given. Therefore, donor type was entered into the
multiple regression model. A multiple regression anal-
ysis then identiﬁed male sex (  .97; P  .027) and
unrelated donor grafts (  .83; P  .039) as signiﬁ-
cant factors.
DISCUSSION
To our knowledge, this article describes the larg-
est series that describes the risk factors for and the
clinical course of HC in children after allogeneic
BMT. We found that children who received a graft
with a lower total nucleated cell count, received a T
cell–depleted graft, received an unrelated donor graft,
or underwent an ATG-containing conditioning regi-
men were at increased risk for HC after allogeneic
BMT.
The incidence of HC in our series is comparable
to that reported in other series of patients undergoing
allogeneic HSCT [1-3]. In our study, all patients who
received cyclophosphamide also received mesna uro-
protection and intravenous hydration—interventions
that have been shown to reduce the incidence of HC
caused by cyclophosphamide treatment [14].
In our series, the cyclophosphamide dose did not
affect the risk of HC. Other studies have likewise not
demonstrated any relationship between HC and the
dose of cyclophosphamide [14,15]. The use of busul-
fan in the conditioning regimen has been reported to
be a risk factor for HC in several series of predomi-
nantly adult patients [1-3], but in our series, only 1
patient received busulfan and did not experience HC.
In a previous study at our institution [16], TBI was
identiﬁed as a risk factor for adenovirus infection;
however, we were not able to investigate TBI in this
study. This may not have been corroborated in this
study because adenoviral infection does have other
manifestations that may occur without HC.
Although other investigators have identiﬁed
GVHD as a risk factor for HC, our study did not
corroborate this ﬁnding [1-3]. This discrepancy may
be the result of the low rates of acute and chronic
GVHD observed with the method of T-cell depletion
at our institution [7]. In the univariate analysis, pa-
tients who received grafts with a lower total number of
nucleated cells or T cell–depleted grafts were more
likely to develop HC. This observation may be attrib-
utable to the more rapid hematologic and immuno-
logic recovery seen in patients who receive grafts that
contain more nucleated cells [17].
Our study identiﬁed several factors (unrelated do-
nor grafts and male sex) that were associated with an
increased risk of HC. Our series found that recipients
of unrelated donor grafts were more likely to develop
HC. In our study, recipients of unrelated donor grafts
received T cell–depleted grafts and ATG-containing
conditioning regimens, both of which are known to
result in signiﬁcant immunosuppression. Considered
in toto, these may be surrogate markers of the immu-
nocompromised state after BMT. Unfortunately, im-
mune reconstitution studies were not serially per-
formed in these patients. Other series have described
HC resulting from viral infections in immunocompro-
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mised patients [18-22]. A recent case report observed
an inverse association between the onset of GVHD
and systemic adenovirus infection [23]. In addition,
the use of ATG in preparative regimens or as treat-
ment for GVHD has been associated with infectious
complications, particularly viruses [24-27]. The low
nucleated cell dose in HC patients did not result in
delayed neutrophil or platelet engraftment compared
with controls in our series; therefore, prolonged neu-
tropenia is unlikely to have resulted in an increased
period of infection risk. It is possible that the recovery
in lymphocyte number and function may have been
delayed in recipients of T cell–depleted grafts, thus
putting the patients at risk for infection.
Pathogens known to cause HC were identiﬁed
from urine samples in only 4 patients: 3 patients were
infected with adenovirus, and 1 was infected with
CMV [28]. No fungal infection was detected. Because
polymerase chain reaction as surveillance testing of
peripheral blood or urine samples was not routinely
performed during the study period, all pathogens were
likely not detected. Many viral infections, including
polyomaviruses such as BK and JC viruses, can be
extremely difﬁcult to detect by typical viral culture
[29,30]. The use of ganciclovir prophylaxis likely re-
sulted in a low rate of CMV reactivation and may have
reduced other viral infections as well. The routine use
of sensitive screening and diagnostic assays to detect
potential pathogens may increase the ability to detect
pathogens.
Various therapeutic interventions for patients with
HC have been reported, with varying degrees of suc-
cess [24-28,31-37]. For most of the patients in our
study, conservative management achieved resolution
of HC: the HC resolved in 5 patients without contin-
uous bladder irrigation or surgical intervention and in
an additional 13 patients with continuous bladder ir-
rigation alone. However, for some patients with HC
that did not respond to these measures, interventions
such as cystoscopy with cauterization or instillation
were successful. Although we recommended cystec-
tomy for 1 patient, no patient in our series underwent
cystectomy, an intervention that others have reported
as necessary for the treatment of extraordinarily severe
HC [38]. However, HC was refractory to these inter-
ventions in 12 patients. Two patients experienced per-
foration of their bladders.
In summary, the incidence of HC in our series of
children is similar to that reported in other large series
of predominantly adult recipients. Although our study
did not conﬁrm risk factors for HC identiﬁed in other
studies of cohorts comprised primarily of adult pa-
tients undergoing autologous or allogeneic BMT, it
did show that older patients were more likely to de-
velop HC.We found that male patients were at higher
risk of HC. We also identiﬁed recipients of unrelated
donor grafts as being high risk of severe HC, likely
because of the use of T-cell depletion, the low cell
content of the graft, and the use of ATG. These
factors are reﬂective of the immunocompromised state
after BMT. Improved diagnostic and screening meth-
ods, such as polymerase chain reaction assays, that are
now available to identify infectious agents should be
incorporated into evaluations of patients who have
undergone HSCT and are at risk for HC, allowing
treatment with appropriate medications [39].
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